← Leaderboards
Brian Michael Barth
University Of New Hampshire
$635,576
Attributed
$635,576
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $161.7K · FY2016–20$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$635,576 · 2
By mechanism
K22$485,076 · 1
R03$150,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Ceramides”
- Yusuf Awni Hannun · Medical University Of South Carolina$31,236,776
- Besim Ogretmen · Medical University Of South Carolina$16,800,540
- Scott A Summers · Colorado State University-Fort Collins$15,094,141
- Pin-Lan Li · Medical College Of Wisconsin$14,567,134
- Richard N Kolesnick · Sloan-Kettering Inst Can Research$13,993,408
- Susan J Sumner · Research Triangle Institute$13,509,958
Research focus
CeramidesIncidenceMetabolismSphingolipidsMolecularCancer CellCell PhysiologyInhibitor/AntagonistMolecular AbnormalityResistanceRegulationPathway InteractionsBaseCombinatorialAcute Myelocytic LeukemiaBiologyAnalogDesignChemotherapyAdultChromosome AbnormalityDevelopment PlansCareer DevelopmentCareer
Grant awards (5)
Combinatorial Decitabine and Liposomal Ceramide for Acute Myeloid Leukemia$76,657
R03 · FY2020 · CA · contact PI
Combinatorial Decitabine and Liposomal Ceramide for Acute Myeloid Leukemia$73,843
R03 · FY2020 · CA · contact PI
Regulation of Ceramide-Based Therapeutics in Acute Myeloid Leukemia$161,692
K22 · FY2018 · CA · contact PI
Regulation of Ceramide-Based Therapeutics in Acute Myeloid Leukemia$161,692
K22 · FY2017 · CA · contact PI
Regulation of Ceramide-Based Therapeutics in Acute Myeloid Leukemia$161,692
K22 · FY2016 · CA · contact PI